Literature DB >> 8885772

Group B Streptococcus and preterm premature rupture of membranes: a randomized, double-blind clinical trial of antepartum ampicillin.

I A Grable1, P M Garcia, D Perry, M L Socol.   

Abstract

OBJECTIVE: Our purpose was to determine whether ampicillin prolongs the latency period after preterm premature rupture of membranes in patients colonized with group B Streptococcus. STUDY
DESIGN: Sixty patients presenting at < or = 35 weeks' gestation with preterm premature rupture of membranes were included in the study. Cervical, vaginal, and perianal cultures for group B premature rupture were obtained. The participants then were randomized to receive either ampicillin or placebo intravenously for 24 hours and then orally until hospital discharge or delivery. All patients were treated without the use of tocolytic drugs. The chi(2) test, Fisher exact test, Student t test, and Wilcoxon signed-rank test were used for statistical analysis when appropriate.
RESULTS: Fifteen patients had cultures positive for group B Streptococcus. Patients with cultures positive for group B Streptococcus who received ampicillin (n = 8) were more likely not to have been delivered of their infants 48 hours after preterm premature rupture of membranes than patients who received placebo (n = 7), a statistically significant difference (100% vs 43%; p = 0.01; relative risk 2.3; 95% confidence interval 1.2 to 4.5). Seven days after preterm premature rupture of membranes, however, there was no significant difference in percentage of patients with cultures positive for group B Streptococcus who remained undelivered (63% vs 29%; p = 0.19; relative risk, 2.2; 95% confidence interval 0.7 to 7.1). Among patients with cultures negative for group B Streptococcus, there was a trend for patients who received ampicillin to remain undelivered 48 hours after preterm premature rupture of membranes compared with those who received placebo, but the difference was not statistically significant (87% vs 64%; p = 0.07; relative risk, 1.4; 95% confidence interval 1.0 to 1.9). There also was no difference in percentage of patients with cultures negative for group B Streptococcus who remained undelivered 7 days after preterm premature rupture of membranes 39% vs 27%; p = 0.40; relative risk, 1.4; 95% confidence interval 0.61 to 3.3). There were no differences between the treatment and placebo arms of the group B Streptococcus positive and negative cohorts in incidence of cesarean section, chorioamnionitis, postpartum endometritis, or neonatal infectious morbidity.
CONCLUSION: Use of antibiotics increases the percentage of patients with cultures positive for group B Streptococcus who remain undelivered 48 hours after preterm premature rupture of membranes. Antibiotic therapy may provide a window of opportunity for maternal treatment with corticosteroids to decrease the risk for neonatal morbidity among these preterm gestations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885772     DOI: 10.1016/s0002-9378(96)80049-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

Review 1.  Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis.

Authors:  Ronald F Lamont; Chia-Ling Nhan-Chang; Jack D Sobel; Kimberly Workowski; Agustin Conde-Agudelo; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2011-04-02       Impact factor: 8.661

2.  Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes.

Authors:  Daniel B DiGiulio; Roberto Romero; Juan Pedro Kusanovic; Ricardo Gómez; Chong Jai Kim; Kimberley S Seok; Francesca Gotsch; Shali Mazaki-Tovi; Edi Vaisbuch; Katherine Sanders; Elisabeth M Bik; Tinnakorn Chaiworapongsa; Enrique Oyarzún; David A Relman
Journal:  Am J Reprod Immunol       Date:  2010-03-21       Impact factor: 3.886

Review 3.  Antibiotics for pre-term pre-labour rupture of membranes: prevention of neonatal deaths due to complications of pre-term birth and infection.

Authors:  Simon Cousens; Hannah Blencowe; Michael Gravett; Joy E Lawn
Journal:  Int J Epidemiol       Date:  2010-04       Impact factor: 7.196

4.  A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Chan-Wook Park; Joong Shin Park; Jong Kwan Jun; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-16

5.  A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-12-02

6.  17-Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double-blind, randomized clinical trial.

Authors:  C Andrew Combs; Thomas J Garite; Kimberly Maurel; Kimberly Mallory; Rodney K Edwards; George Lu; Richard Porreco; Anita Das
Journal:  BMC Res Notes       Date:  2011-12-29

7.  Antibiotic administration reduces the rate of intraamniotic inflammation in preterm prelabor rupture of the membranes.

Authors:  Marian Kacerovsky; Roberto Romero; Martin Stepan; Jaroslav Stranik; Jan Maly; Lenka Pliskova; Radka Bolehovska; Vladimir Palicka; Helena Zemlickova; Helena Hornychova; Jiri Spacek; Bo Jacobsson; Percy Pacora; Ivana Musilova
Journal:  Am J Obstet Gynecol       Date:  2020-07       Impact factor: 10.693

8.  Developing a Core Outcome Set for the Evaluation of Antibiotic Use in Prelabor Rupture of Membranes: A Systematic Review and Semi-Structured Interview.

Authors:  Dan Liu; Lin Wu; Jiefeng Luo; Siyu Li; Yan Liu; Chuan Zhang; Linan Zeng; Qin Yu; Lingli Zhang
Journal:  Front Pharmacol       Date:  2022-08-01       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.